Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7X-Rays 6Vincristine 6Phantoms, Imaging 6Cyclophosphamide 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Ifosfamide 5Etoposide 5Biopsy 5Temozolomide 4Radiotherapy 4Doxorubicin 4Dactinomycin 4Topotecan 3Melphalan 3Irinotecan 3Filgrastim 3Carboplatin 3Busulfan 3ulixertinib 2tipifarnib 2tazemetostat 2tanespimycin 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ixabepilone 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroectodermal Tumors, Primitive, Peripheral × efineptakin alfa × Clear all
NCT00923351 2018-06-15

Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
44 enrolled 13 charts
CNSSarcoma

Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡